Protease inhibitor and nonnucleoside reverse transcriptase inhibitor concentrations in the genital tract of HIV-1-infected women.
about
Barriers to a cure for HIV in womenAntiretroviral pharmacology in mucosal tissuesClinical parameters essential to methodology and interpretation of mucosal responsesCompartmentalization of HIV-1 within the female genital tract is due to monotypic and low-diversity variants not distinct viral populations.Single and multiple dose pharmacokinetics of dolutegravir in the genital tract of HIV-negative women.Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxisDifferential extracellular and intracellular concentrations of zidovudine and lamivudine in semen and plasma of HIV-1-infected men.Pharmacokinetics of antiretrovirals in genital secretions and anatomic sites of HIV transmission: implications for HIV prevention.Darunavir, ritonavir, and etravirine pharmacokinetics in the cervicovaginal fluid and blood plasma of HIV-infected women.Cervical shedding of HIV-1 RNA among women with low levels of viremia while receiving highly active antiretroviral therapyViral sequence analysis from HIV-infected mothers and infants: molecular evolution, diversity, and risk factors for mother-to-child transmission.Antiretroviral-based HIV prevention strategies for women.Pharmacokinetics of antiretrovirals in mucosal tissueHIV treatment as prevention and HPTN 052.Human immunodeficiency viruses appear compartmentalized to the female genital tract in cross-sectional analyses but genital lineages do not persist over time.Novel methodology for antiretroviral quantitation in the female genital tractGenital tract, cord blood, and amniotic fluid exposures of seven antiretroviral drugs during and after pregnancy in human immunodeficiency virus type 1-infected women.Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women.HIV PrEP Trials: The Road to Success.The future of HIV microbicides: challenges and opportunities.Effect of HIV infection and menopause status on raltegravir pharmacokinetics in the blood and genital tract.Prophylaxis and treatment of HIV-1 infection in pregnancy: Swedish recommendations 2013.From modeling to morals: imagining the future of HIV PREP in Lesotho.Cervicovaginal and Rectal Fluid as a Surrogate Marker of Antiretroviral Tissue Concentration: Implications for Clinical Trial Design.Antiretroviral drug concentrations and HIV RNA in the genital tract of HIV-infected women receiving long-term highly active antiretroviral therapy.
P2860
Q26768632-EE5B4F03-8BED-488F-8EB1-98F59FC5C5CAQ27014675-DC5FAF7D-D886-484A-9188-B809C23730A9Q30398452-BD2FA9E9-0FFF-4588-99B6-FAABA4C1EB87Q33505667-A1C200E6-9C82-4FD4-967A-CEF4076EB32DQ33686465-84794F30-8EA9-4F4C-B264-D650DA68C6BBQ33821257-213E085C-FD9D-4461-B98C-9FAAB15858C8Q33821263-A7FFEF64-5785-4B2B-8D82-09102D1932C3Q33888718-AB4CBCFD-6F3C-4EDA-BB67-B4EC7879D069Q34737260-F2B0250C-6649-4DBF-B08E-88E9BC5150F5Q35077988-2C321F16-12A0-45D9-91AA-B17DB96A516DQ35219574-951A47A1-32AA-4A2D-B845-653F591407D0Q35237188-7E2324E5-25E6-43C1-A232-E85A993213C6Q35838594-D46803A9-2C0D-4910-8AF2-6A7E85D2698BQ36364604-37AF4451-4B52-47A0-8B01-DA39DFD8DFF1Q36702615-766D2D68-5469-46A4-AA41-2A732401BADCQ37158604-EC1DF1FE-E2EA-4D06-A4F8-9A39B4AE7BD6Q37204271-C369447B-8071-467F-8C2A-AB1061E09C23Q37362444-1B154E3F-F9C0-4C7A-8847-990529C625E1Q37438644-C085297B-5D7C-4ECE-8DBE-7D30743F97F4Q37448790-45893112-457A-475D-A8C1-090A7311A696Q37592039-DFC23772-E9CA-476C-96C3-0BABE5393964Q38206255-59522D87-BE6A-4425-91B6-6CB3887DF1DEQ39396606-A07F2C3E-B11A-4C3C-ADDD-E4376A65F6A2Q40747185-ED01AA5C-FDD7-4D93-AF5F-53683FB5516EQ46791174-3EA2ACBE-4083-4BF1-B6E8-FF4B72579A95
P2860
Protease inhibitor and nonnucleoside reverse transcriptase inhibitor concentrations in the genital tract of HIV-1-infected women.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Protease inhibitor and nonnucl ...... tract of HIV-1-infected women.
@en
Protease inhibitor and nonnucl ...... tract of HIV-1-infected women.
@nl
type
label
Protease inhibitor and nonnucl ...... tract of HIV-1-infected women.
@en
Protease inhibitor and nonnucl ...... tract of HIV-1-infected women.
@nl
prefLabel
Protease inhibitor and nonnucl ...... tract of HIV-1-infected women.
@en
Protease inhibitor and nonnucl ...... tract of HIV-1-infected women.
@nl
P2093
P1476
Protease inhibitor and nonnucl ...... tract of HIV-1-infected women.
@en
P2093
Amanda H Corbett
Angela D M Kashuba
Leslie Petch
Naser Rezk
Sherene S Min
Susan A Fiscus
Susan Cu-Uvin
P304
P356
10.1097/00126334-200412150-00008
P407
P577
2004-12-01T00:00:00Z